Coulter Partners announces top hires for VC & PE portfolio companies Q4-2022

Search Highlights

Recent top global hires for Venture Capital and Private Equity backed companies, covering a broad range of disciplines and sectors across Life Sciences, Health, and Tech.

This quarter’s successful placements include:
  • CEO, regenerative medicine (UK)
  • CEO, implantable cardiac devices (France)
  • Chief Business Officer, neurodegenerative diseases (Netherlands)
  • Chief Medical Officer, age-related therapeutics (US)
  • Chief Financial Officer, RNA-based therapeutics (Germany)
  • SVP, GM Biosurgery & EMEA Sales, surgical equipment (Belgium)
  • Head of Regulatory Affairs, in vivo gene editing (US)
  • Country CEO, veterinary services (Nordics)
  • UK General Manager, digital devices and therapeutics (US)
  • VP Immunology / Translation, small molecule therapeutics (UK)
  • VP Global Leader of Manufacturing and Operations, DNA sequencing (UK)
  • Head of Product, AI-enabled analytics (Belgium)
  • 2 x Board Directors, infectious diseases (UK)
  • Chair, Active Pharmaceutical Ingredients (APIs) (Switzerland)

Newly opened projects include:
  • CEO, RNA vaccines (UK)
  • CEO, vaccines (Switzerland)
  • CEO, specialist CRO (Australia)
  • Chief Business Officer, precision medicines (US)
  • Chief Scientific Officer, retinal vascular diseases (Nordics)
  • Chief Technology Officer, AAV gene therapy (US)
  • Chief of Staff, ophthalmic medical devices (France)
  • Chief Technology & Operations Officer, plant-based foods (Nordics)
  • VP, Antibody Engineering & Protein Sciences, drug discovery services (US)
  • Head of Translational Medicine, cell therapy biotech (Switzerland)
  • VP Business Development Oncology, quantum physics enabled drug development (US)
  • Investment Manager Digital Health, VC investor (Netherlands)
  • Chair, AI for drug discovery (Central & Eastern Europe)


More within